Details der Publikation - Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma

Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma / Wes Nakchbandi, Herwart Müller, Manfred V. Singer, Matthias Löhr & Inaam A. Nakchbandi

OBJECTIVE: To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin. MATERIAL AND METHODS: A retrospective analysis was performed on 180 patients with pancreatic carcinoma. Patients received one of seven regimens of chemotherapy. Unrelated to the type of chemotherapy, some patients received 1.25 mg warfarin daily. The primary end-point was median survival. RESULTS: Treatment with warfarin resulted in improved median survival from the start of regional therapy (warfarin versus no warfarin: 5.0 versus 2.3 months, n = 111 versus 69; p < 0.0001). This effect was not dependent on the type of chemotherapy used. Among the seven regimens examined, the one consisting of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest median survival of 5.1 months from the start of regional therapy (p = 0.006) and 12.7 months from diagnosis. This regimen combined with warfarin was associated with improved median survival (7.1 months, n = 32). CONCLUSIONS: Treatment with low-dose warfarin improved survival irrespective of the chemotherapy received. Of the regimens examined, the combination of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest survival time. Survival was increased further by the addition of warfarin. These data provide a rationale, based on safety and efficacy, for a definitive study on the use of warfarin and combined regional and systemic chemotherapy in patients with pancreatic carcinoma..

Medienart:	E-Artikel

Erscheinungsjahr:	2006
Erschienen:	2006

Enthalten in:	Zur Gesamtaufnahme - volume:41
Enthalten in:	Scandinavian journal of gastroenterology - 41(2006), 9, Seite 1095-1104

Sprache:	Englisch

Beteiligte Personen:	Nakchbandi, Wes, 1963- [VerfasserIn] Müller, Herwart [VerfasserIn] Singer, Manfred V., 1945- [VerfasserIn] Löhr, J.-Matthias [VerfasserIn] Nakchbandi, Inaam, 1967- [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Antibiotics, Antineoplastic Anticoagulants Carcinoma Deoxycytidine Dose-Response Relationship, Drug Drug Therapy, Combination Female Follow-Up Studies Humans Immunosuppressive Agents Injections, Intra-Arterial Male Middle Aged Mitomycin Pancreatic Neoplasms Retrospective Studies Ribonucleotide Reductases Survival Rate Treatment Outcome Warfarin

Anmerkungen:	Elektronische Reproduktion der Druck-Ausgabe Gesehen am 30.06.2021

Umfang:	10

doi:	10.1080/00365520600575720

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1761552066

Internformat


LEADER	01000caa a2200265 4500
001	1761552066
003	DE-627
005	20230426153135.0
007	cr uuu---uuuuu
008	210630s2006 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1080/00365520600575720 \|2 doi
035			\|a (DE-627)1761552066
035			\|a (DE-599)KXP1761552066
035			\|a (OCoLC)1341417803
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
100	1		\|a Nakchbandi, Wes \|d 1963- \|e verfasserin \|0 (DE-588)129877840 \|0 (DE-627)482373601 \|0 (DE-576)297882767 \|4 aut
245	1	0	\|a Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma \|c Wes Nakchbandi, Herwart Müller, Manfred V. Singer, Matthias Löhr & Inaam A. Nakchbandi
264		1	\|c 2006
300			\|a 10
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a Elektronische Reproduktion der Druck-Ausgabe
500			\|a Gesehen am 30.06.2021
520			\|a OBJECTIVE: To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin. MATERIAL AND METHODS: A retrospective analysis was performed on 180 patients with pancreatic carcinoma. Patients received one of seven regimens of chemotherapy. Unrelated to the type of chemotherapy, some patients received 1.25 mg warfarin daily. The primary end-point was median survival. RESULTS: Treatment with warfarin resulted in improved median survival from the start of regional therapy (warfarin versus no warfarin: 5.0 versus 2.3 months, n = 111 versus 69; p < 0.0001). This effect was not dependent on the type of chemotherapy used. Among the seven regimens examined, the one consisting of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest median survival of 5.1 months from the start of regional therapy (p = 0.006) and 12.7 months from diagnosis. This regimen combined with warfarin was associated with improved median survival (7.1 months, n = 32). CONCLUSIONS: Treatment with low-dose warfarin improved survival irrespective of the chemotherapy received. Of the regimens examined, the combination of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest survival time. Survival was increased further by the addition of warfarin. These data provide a rationale, based on safety and efficacy, for a definitive study on the use of warfarin and combined regional and systemic chemotherapy in patients with pancreatic carcinoma.
650		4	\|a Antibiotics, Antineoplastic
650		4	\|a Anticoagulants
650		4	\|a Carcinoma
650		4	\|a Deoxycytidine
650		4	\|a Dose-Response Relationship, Drug
650		4	\|a Drug Therapy, Combination
650		4	\|a Female
650		4	\|a Follow-Up Studies
650		4	\|a Humans
650		4	\|a Immunosuppressive Agents
650		4	\|a Injections, Intra-Arterial
650		4	\|a Male
650		4	\|a Middle Aged
650		4	\|a Mitomycin
650		4	\|a Pancreatic Neoplasms
650		4	\|a Retrospective Studies
650		4	\|a Ribonucleotide Reductases
650		4	\|a Survival Rate
650		4	\|a Treatment Outcome
650		4	\|a Warfarin
700	1		\|a Müller, Herwart \|e verfasserin \|4 aut
700	1		\|a Singer, Manfred V. \|d 1945- \|e verfasserin \|0 (DE-588)121081958 \|0 (DE-627)081074069 \|0 (DE-576)169905330 \|4 aut
700	1		\|a Löhr, J.-Matthias \|e verfasserin \|0 (DE-588)13947241X \|0 (DE-627)611268973 \|0 (DE-576)31199735X \|4 aut
700	1		\|a Nakchbandi, Inaam \|d 1967- \|e verfasserin \|0 (DE-588)142756881 \|0 (DE-627)638931053 \|0 (DE-576)188363874 \|4 aut
773	0	8	\|i Enthalten in \|t Scandinavian journal of gastroenterology \|d Abingdon : Taylor & Francis Group, 1966 \|g 41(2006), 9, Seite 1095-1104 \|h Online-Ressource \|w (DE-627)302725571 \|w (DE-600)1492631-3 \|w (DE-576)088704866 \|x 1502-7708 \|7 nnns
773	1	8	\|g volume:41 \|g year:2006 \|g number:9 \|g pages:1095-1104 \|g extent:10
856	4	0	\|u https://doi.org/10.1080/00365520600575720 \|x Verlag \|x Resolving-System \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ILN_2013
912			\|a ISIL_DE-16-250
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_121
912			\|a GBV_ILN_161
912			\|a GBV_ILN_187
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_374
912			\|a GBV_ILN_602
912			\|a GBV_ILN_647
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2966
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4277
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4346
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4753
936	u	w	\|d 41 \|j 2006 \|e 9 \|h 1095-1104 \|g 10
951			\|a AR
952			\|d 41 \|j 2006 \|e 9 \|h 1095-1104 \|g 10
980			\|2 2013 \|1 01 \|x DE-16-250 \|b 3942561352 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 30-06-21
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 00 \|s s \|a hd2006
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 01 \|s s \|0 (DE-627)1410508463 \|a wissenschaftlicher Artikel (Zeitschrift)
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 02 \|s s \|a per_5
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 03 \|s s \|a s_10
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s p \|0 (DE-627)1480287490 \|a Singer, Manfred V.
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s k \|0 (DE-627)1416468471 \|a II. Medizinische Klinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|a pos_3
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s p \|0 (DE-627)157650378X \|a Löhr, J.-Matthias
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s k \|0 (DE-627)1416468471 \|a II. Medizinische Klinik
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|a pos_4
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s p \|0 (DE-627)1480288292 \|a Nakchbandi, Inaam
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s k \|0 (DE-627)1416466967 \|a Medizinische Fakultät Heidelberg
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s s \|a pos_1

Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma / Wes Nakchbandi, Herwart Müller, Manfred V. Singer, Matthias Löhr & Inaam A. Nakchbandi

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände